Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]
In development
Reference number: GID-TA11278
Expected publication date: TBC
Please note that following on from advice received from the company, the timelines for this appraisal are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this appraisal will be available in due course.
In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.